Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Jan 2018 Sonis OM Rvw Article
(Indeed KMBJN - he has his finger in many an OM pie...)

“Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis”

Stephen T. Sonis & Alessandro Villa
Received 01 Dec 2017, Accepted 10 Jan 2018, Accepted author version posted online: 11 Jan 2018

Behind paywall and only seems author manuscript version is available for now — Abstract below. Maybe someone has access and can summarize the content. Google does reveal a B-OM mention.

Since received Dec 1st pre B-OM Topline results release.

—

http://www.tandfonline.com/doi/abs/10.1080/13543784.2018.1427732

ABSTRACT

Introduction: Oral mucositis is a significant unmet clinical need for many cancer patients. The biological complexity of mucositis’ pathogenesis provides a number of mechanistic targets suitable as pharmacologic targets. The diversity of targets has stimulated drug development in search of an effective intervention. In this paper, we review a range of agents that are currently being evaluated.

Areas covered: Drugs for management of oral mucositis vary in formulation, route of administration and biological target. Most propose to interrupt the initiation of injury by suppressing activation of the innate immune response or countering oxidative stress, or minimizing downstream inflammatory responses. Overwhelmingly, the population most studied is patients being treated with concomitant chemoradiation for cancers of the head and neck as this is the cohort that most consistently suffers severe mucositis for long periods of time. The Phase 2 pipeline is robust. Preliminary data reported for a number of agents is optimistic. Genomics may be important in interpreting and comparing responses to agents across widely demographically diverse populations.

Expert opinion: Oral mucositis remains a significant toxicity for patients undergoing cancer treatment. Incremental reports of successes have been noted for a number of targeted agents.